Evidence map›Paper›PMID 31803483›Full record

ArticleBMJ open diabetes research & care2019

Validity of the FINDRISC as a prediction tool for diabetes in a contemporary Norwegian population: a 10-year follow-up of the HUNT study.

Anne Jølle, Kristian Midthjell, Jostein Holmen, Sven Magnus Carlsen, Jaakko Tuomilehto, Johan Håkon Bjørngaard, Bjørn Olav Åsvold

Registry-linked trialOpen access · goldAbstract readValidation Study
In one paragraph

Article in BMJ open diabetes research & care, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06195566 (Physics Informed Machine Learning-based Prediction and Reversion of Impaired Fasting Glucose Management), which is not on this map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06195566 completednot on this mapstarted 2024, after this paper: background citation

Physics Informed Machine Learning-based Prediction and Reversion of Impaired Fasting Glucose Management

TypeobservationalSponsorJelizaveta SokolovskaRan2024 to 2025Enrolled77ConditionsPrediabetic State, Body Weight, Overweight or Obesity, Life Style, Healthy
3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Assessing the Risk of Type 2 Diabetes Among University Employees in Kuwait: A Cross-Sectional Study.International journal of environmental research and public health · 2026
    Article
  5. Article
  6. Improving Diabetes and Pre-Diabetes Detection in the UK: Insights From HbA1c Screening in an Acute Hospital's Emergency Department.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025
    Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 3 countries.

Anne JølleHUNT Research Center, Department of Public Health and Nursing, NTNU, Levanger, Norway.ORCID 0000-0001-7048-9719
Kristian MidthjellHUNT Research Center, Department of Public Health and Nursing, NTNU, Levanger, Norway.
Jostein HolmenHUNT Research Center, Department of Public Health and Nursing, NTNU, Levanger, Norway.
Sven Magnus CarlsenDepartment of Endocrinology, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
Jaakko TuomilehtoDepartment of Public Health Solutions, National Institute for Health and Welfare, Helsinki, Finland.
Johan Håkon BjørngaardDepartment of Public Health and Nursing, NTNU, Trondheim, Norway.
Bjørn Olav ÅsvoldHUNT Research Center, Department of Public Health and Nursing, NTNU, Levanger, Norway.ORCID 0000-0003-3837-2101
St Olav's University Hospital · NOUniversity of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The Finnish Diabetes Risk Score (FINDRISC) is a recommended tool for type 2 diabetes prediction. There is a lack of studies examining the performance of the current 0-26 point FINDRISC scale. We examined the validity of FINDRISC in a contemporary Norwegian risk environment. Research design and methods: We followed 47 804 participants without known diabetes and aged ≥20 years in the HUNT3 survey (2006-2008) by linkage to information on glucose-lowering drug dispensing in the Norwegian Prescription Database (2004-2016). We estimated the C-statistic, sensitivity and specificity of FINDRISC as predictor of incident diabetes, as indicated by incident use of glucose-lowering drugs. We estimated the 10-year cumulative diabetes incidence by categories of FINDRISC. Results: The C-statistic (95% CI) of FINDRISC in predicting future diabetes was 0.77 (0.76 to 0.78). FINDRISC ≥15 (the conventional cut-off value) had a sensitivity of 38% and a specificity of 90%. The 10-year cumulative diabetes incidence (95% CI) was 4.0% (3.8% to 4.2%) in the entire study population, 13.5% (12.5% to 14.5%) for people with FINDRISC ≥15 and 2.8% (2.6% to 3.0%) for people with FINDRISC <15. Thus, FINDRISC ≥15 had a positive predictive value of 13.5% and a negative predictive value of 97.2% for diabetes within the next 10 years. To approach a similar sensitivity as in the study in which FINDRISC was developed, we would have to lower the cut-off value for elevated FINDRISC to ≥11. This would yield a sensitivity of 73%, specificity of 67%, positive predictive value of 7.7% and negative predictive value of 98.5%. Conclusions: The validity of FINDRISC and the risk of diabetes among people with FINDRISC ≥15 is substantially lower in the contemporary Norwegian population than assumed in official guidelines. To identify ~3/4 of those developing diabetes within the next 10 years, we would have to lower the threshold for elevated FINDRISC to ≥11, which would label ~1/3 of the entire adult population as having an elevated FINDRISC necessitating a glycemia assessment.

Indexed as

AgedBiomarkersCross-Sectional StudiesDiabetes Mellitus, Type 2FemaleFollow-Up StudiesHumansIncidenceMaleMass ScreeningMiddle AgedNorwayPrognosisProspective StudiesRisk AssessmentSurveys and QuestionnairesBiomarkersepidemiologyprediction and prevention

Identifiers

PMID31803483
PMCPMC6887494
OpenAlexW2990989561

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.